Organon & Co. (0A9W.IL)
| Previous close | 21.36 |
| Open | 21.49 |
| Bid | 0.00 x N/A |
| Ask | 0.00 x N/A |
| Day's range | 21.49 - 21.90 |
| 52-week range | 10.89 - 24.05 |
| Volume | |
| Avg. volume | 2,260 |
| Market cap | 6.061B |
| Beta (5Y monthly) | 0.87 |
| PE ratio (TTM) | 7.42 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 1.12 (6.99%) |
| Ex-dividend date | 17 Aug 2023 |
| 1y target est | N/A |
- Business Wire
Organon Announces Pricing of $1.0 Billion Senior Notes Offering
JERSEY CITY, N.J., May 08, 2024--Organon (NYSE: OGN) ("Organon"), a global healthcare company with a focus on women’s health, announced today that it, together with Organon Foreign Debt Co-Issuer B.V., a direct wholly-owned subsidiary of Organon, as co-issuer (the "Co-Issuer" and, together with Organon, the "Companies"), have priced an offering of $500 million of 6.750% senior secured notes due 2034 (the "Secured Notes") and $500 million of 7.875% senior unsecured notes due 2034 (the "Unsecured
- Business Wire
Organon Announces Proposed $1.0 Billion Senior Notes Offering
JERSEY CITY, N.J., May 07, 2024--Organon (NYSE: OGN) ("Organon"), a global healthcare company with a focus on women’s health, announced today that it, together with Organon Foreign Debt Co-Issuer B.V., a direct wholly-owned subsidiary of Organon, as co-issuer (the "Co-Issuer" and, together with Organon, the "Companies"), plan to offer, subject to market conditions, $500 million of senior secured notes due 2034 (the "secured notes") and $500 million of senior unsecured notes due 2034 (the "unsecu
- Business Wire
Organon Reports Results for the First Quarter Ended March 31, 2024
JERSEY CITY, N.J., May 02, 2024--Organon Reports Results for the First Quarter Ended March 31, 2024
